Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Gains from Investment Securities (2023 - 2025)

Historic Gains from Investment Securities for Immunome (IMNM) over the last 3 years, with Q3 2025 value amounting to $5.4 million.

  • Immunome's Gains from Investment Securities rose 414.34% to $5.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.4 million, marking a year-over-year increase of 414.34%. This contributed to the annual value of $6.6 million for FY2024, which is 1707.29% down from last year.
  • Per Immunome's latest filing, its Gains from Investment Securities stood at $5.4 million for Q3 2025, which was up 414.34% from $902684.0 recorded in Q2 2025.
  • In the past 5 years, Immunome's Gains from Investment Securities ranged from a high of $8.5 million in Q2 2024 and a low of $902684.0 during Q2 2025
  • In the last 3 years, Immunome's Gains from Investment Securities had a median value of $3.0 million in 2023 and averaged $3.9 million.
  • As far as peak fluctuations go, Immunome's Gains from Investment Securities skyrocketed by 18103.27% in 2024, and later tumbled by 8942.75% in 2025.
  • Quarter analysis of 3 years shows Immunome's Gains from Investment Securities stood at $5.8 million in 2023, then tumbled by 62.07% to $2.2 million in 2024, then surged by 144.85% to $5.4 million in 2025.
  • Its Gains from Investment Securities stands at $5.4 million for Q3 2025, versus $902684.0 for Q2 2025 and $2.1 million for Q1 2025.